Literature DB >> 8791179

A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care.

J Forder1, S Kavanagh, A Fenyo.   

Abstract

There has been considerable debate concerning the cost-effectiveness of selective serotonin re-uptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) thus far using crude prescription price comparisons or reductionist decision-analytic models. This paper employs a retrospective quasi-experimental design where data on service utilisation, use of medication and informal care were collected for two groups of patients in general practice settings. The mean cost of treatment was marginally greater for those people receiving TCA medication due to greater use of psychiatric services. Factors such as age, previous depression and concomitant physical illness are all associated with greater treatment costs. Further analysis using a prospective design is recommended.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791179     DOI: 10.1016/0165-0327(95)00098-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Costs of antidepressant overdose: a preliminary study.

Authors:  N Kapur; A House; F Creed; E Feldman; T Friedman; E Guthrie
Journal:  Br J Gen Pract       Date:  1999-09       Impact factor: 5.386

Review 2.  Pharmacoeconomic evaluation of antidepressants : a critical appraisal of methods.

Authors:  Sheikh Usman Iqbal; Mark Prashker
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.

Authors:  R I Griffiths; E M Sullivan; R G Frank; M J Strauss; R J Herbert; J Clouse; H H Goldman
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 4.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

5.  Selective serotonin reuptake inhibitor use in primary care: a 5-year naturalistic study.

Authors:  J Donoghue
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

7.  Cost-effectiveness of a primary care depression intervention.

Authors:  Jeffrey M Pyne; Kathryn M Rost; Mingliang Zhang; D Keith Williams; Jeffrey Smith; John Fortney
Journal:  J Gen Intern Med       Date:  2003-06       Impact factor: 5.128

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.